Free Trial

HC Wainwright Analysts Lower Earnings Estimates for Innoviva

Innoviva logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its Q4 2026 EPS forecast for Innoviva to $0.53 from $0.54. It also forecast EPS of $0.57 for Q3 2027 and $0.63 for Q4 2027; the current full-year consensus estimate is $1.52 per share.
  • Innoviva’s latest quarter missed expectations, reporting a loss of $1.03 per share versus the $0.52 consensus and revenue of $106.12 million versus estimates of $115.31 million.
  • Analyst sentiment remains moderately positive: MarketBeat reports five Buy ratings and one Hold, with a $39 average price target. Shares opened at $19.03.
  • Five stocks we like better than Innoviva.

Innoviva, Inc. (NASDAQ:INVA - Free Report) - Investment analysts at HC Wainwright reduced their Q4 2026 earnings estimates for Innoviva in a note issued to investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of $0.53 per share for the quarter, down from their prior forecast of $0.54. The consensus estimate for Innoviva's current full-year earnings is $1.52 per share. HC Wainwright also issued estimates for Innoviva's Q3 2027 earnings at $0.57 EPS and Q4 2027 earnings at $0.63 EPS.

Innoviva (NASDAQ:INVA - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of $0.52 by ($1.55). The firm had revenue of $106.12 million for the quarter, compared to analyst estimates of $115.31 million. Innoviva had a return on equity of 22.91% and a net margin of 44.13%.

A number of other equities research analysts have also recently weighed in on the company. Wall Street Zen cut Innoviva from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Oppenheimer cut their price objective on Innoviva from $35.00 to $34.00 and set an "outperform" rating for the company in a research report on Thursday, November 5th. Cantor Fitzgerald reduced their price objective on Innoviva from $36.00 to $34.00 and set an "overweight" rating on the stock in a research note on Friday, August 7th. Weiss Ratings raised Innoviva from a "hold (c+)" rating to a "buy (b)" rating in a research note on Monday, November 9th. Finally, Zacks Research upgraded Innoviva from a "strong sell" rating to a "hold" rating in a report on Monday, August 31st. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $39.00.

View Our Latest Research Report on Innoviva

Innoviva Price Performance

Shares of INVA opened at $19.03 on Monday. The company has a market capitalization of $1.35 billion, a P/E ratio of 9.56, a PEG ratio of 4.16 and a beta of 0.38. The company has a debt-to-equity ratio of 0.23, a current ratio of 15.44 and a quick ratio of 14.58. Innoviva has a one year low of $18.66 and a one year high of $25.15. The business's 50 day simple moving average is $20.70 and its 200-day simple moving average is $21.85.

Hedge Funds Weigh In On Innoviva

A number of large investors have recently modified their holdings of INVA. Jump Financial LLC acquired a new stake in shares of Innoviva in the third quarter valued at approximately $401,000. Empowered Funds LLC raised its position in Innoviva by 28.1% in the 3rd quarter. Empowered Funds LLC now owns 417,698 shares of the biotechnology company's stock worth $8,859,000 after purchasing an additional 91,501 shares during the last quarter. First Trust Advisors LP raised its position in Innoviva by 18.9% in the 3rd quarter. First Trust Advisors LP now owns 339,715 shares of the biotechnology company's stock worth $7,205,000 after purchasing an additional 53,968 shares during the last quarter. Public Sector Pension Investment Board raised its position in Innoviva by 2.0% in the 3rd quarter. Public Sector Pension Investment Board now owns 245,736 shares of the biotechnology company's stock worth $5,149,000 after purchasing an additional 4,828 shares during the last quarter. Finally, Global Retirement Partners LLC lifted its holdings in Innoviva by 7,322.2% during the 3rd quarter. Global Retirement Partners LLC now owns 6,012 shares of the biotechnology company's stock worth $128,000 after buying an additional 5,931 shares in the last quarter. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Innoviva Company Profile

(Get Free Report)

Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.

Further Reading

Earnings History and Estimates for Innoviva (NASDAQ:INVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Innoviva Right Now?

Before you consider Innoviva, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innoviva wasn't on the list.

While Innoviva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines